{"protocolSection":{"identificationModule":{"nctId":"NCT02109484","nctIdAliases":["NCT02132156"],"orgStudyIdInfo":{"id":"VAC-013"},"organization":{"fullName":"PATH","class":"OTHER"},"briefTitle":"Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants","officialTitle":"Phase I/II Descending Age Double-blinded Randomized Placebo-controlled Dose Escalation Study to Examine the Safety Reactogenicity Tolerability & Immunogenicity of the P2-VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers & Infants"},"statusModule":{"statusVerifiedDate":"2017-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-03"},"primaryCompletionDateStruct":{"date":"2015-11","type":"ACTUAL"},"completionDateStruct":{"date":"2015-11","type":"ACTUAL"},"studyFirstSubmitDate":"2014-04-04","studyFirstSubmitQcDate":"2014-04-07","studyFirstPostDateStruct":{"date":"2014-04-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-05-10","resultsFirstSubmitQcDate":"2017-11-10","resultsFirstPostDateStruct":{"date":"2017-12-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2017-11-10","lastUpdatePostDateStruct":{"date":"2017-12-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"PATH","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is is a study of a parenteral rotavirus vaccine (P2-VP8 subunit rotavirus vaccine). The study will examine the safety and immunogenicity of this vaccine first in healthy South African toddlers. If the safety profile is deemed appropriate, the study will continue to explore the safety and immunogenicity of the vaccine in healthy South African infants.\n\nThe primary safety hypothesis is that the P2-VP8 subunit rotavirus vaccine is safe and well-tolerated in healthy toddlers and infants. The primary immunogenicity hypothesis is that the P2-VP8 subunit rotavirus vaccine is immunogenic in infant participants and will induce an immune response in at least 80% of participants in at least one of the study groups."},"conditionsModule":{"conditions":["Evaluation of a Rotavirus Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":204,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort A P2-VP8 30 mcg","type":"EXPERIMENTAL","description":"Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)","interventionNames":["Biological: P2-VP8 Subunit Vaccine 30 mcg"]},{"label":"Cohort A Placebo","type":"PLACEBO_COMPARATOR","description":"Cohort A toddlers (24-35 mo)","interventionNames":["Other: Placebo"]},{"label":"Cohort A P2-VP8 60 mcg","type":"EXPERIMENTAL","description":"Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)","interventionNames":["Biological: P2-VP8 Subunit Vaccine 60mcg"]},{"label":"Cohort B P2-VP8 10mcg","type":"EXPERIMENTAL","description":"Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)","interventionNames":["Biological: P2-VP8 Subunit Vaccine 10mcg"]},{"label":"Cohort B placebo","type":"PLACEBO_COMPARATOR","description":"Cohort B infants aged 6 to \\< 8 weeks receiving placebo","interventionNames":["Other: Placebo"]},{"label":"Cohort B P2-VP8 30mcg","type":"EXPERIMENTAL","description":"Cohort B infants aged 6 to \\< 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)","interventionNames":["Biological: P2-VP8 Subunit Vaccine 30 mcg"]},{"label":"Cohort B1 P2-VP8 60mcg","type":"EXPERIMENTAL","description":"Cohort B1 Infants aged 6 to \\< 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)","interventionNames":["Biological: P2-VP8 Subunit Vaccine 60mcg"]},{"label":"Cohort A P2-VP8 10mcg","type":"EXPERIMENTAL","description":"Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)","interventionNames":["Biological: P2-VP8 Subunit Vaccine 10mcg"]}],"interventions":[{"type":"BIOLOGICAL","name":"P2-VP8 Subunit Vaccine 10mcg","description":"10 mcg","armGroupLabels":["Cohort A P2-VP8 10mcg","Cohort B P2-VP8 10mcg"]},{"type":"BIOLOGICAL","name":"P2-VP8 Subunit Vaccine 30 mcg","description":"30 mcg","armGroupLabels":["Cohort A P2-VP8 30 mcg","Cohort B P2-VP8 30mcg"]},{"type":"BIOLOGICAL","name":"P2-VP8 Subunit Vaccine 60mcg","description":"60 mcg","armGroupLabels":["Cohort A P2-VP8 60 mcg","Cohort B1 P2-VP8 60mcg"]},{"type":"OTHER","name":"Placebo","armGroupLabels":["Cohort A Placebo","Cohort B placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Vaccine Induced Reactions","description":"Maximum severity of all local reactions or systemic reactogenicity after any vaccination","timeFrame":"7 days following each dose"},{"measure":"Number of Participants With Serious Adverse Events","description":"Number of participants experiencing a Serious Adverse Event within 28 days of a vaccination and at any time during the study","timeFrame":"within 28 days of a study dose and at any time"},{"measure":"Number of Participants Reporting Any Non-Serious Adverse Event","description":"all adverse events will be recorded over the duration of the 6 month follow up period.","timeFrame":"6 mo following first vaccination"},{"measure":"Number/Percentage of Infant Participants With Anti-P2-VP8 IgA to P[8] Seroresponse.","description":"Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third vaccination). Confidence intervals are displayed as percentages.","timeFrame":"Baseline to day 84"},{"measure":"Number/Percentage of Infants With Anti-P2-VP8 IgG to P[8] Seroresponses","description":"Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.","timeFrame":"Baseline to day 84"},{"measure":"Number/Percentage of Infants With Neutralizing Antibody Response to WA Strain (G1[P8])","description":"Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.","timeFrame":"Baseline to Day 84"}],"secondaryOutcomes":[{"measure":"Rotavirus Shedding After Administration of Rotarix in Infants Receiving 3 Doses of Vaccine or Placebo.","description":"Percent of infants who shed rotavirus at any timepoint after receiving 3 doses of study vaccine and one dose of Rotarix. Infants received Rotarix vaccination beginning on Day 84. Stool specimens were collected from these infants on the 5th, 7th and 9th day following first administration of Rotarix. This test was performed as a novel functional assessment of the ability to suppress local gut multiplication of the vaccine strain contained in Rotarix.","timeFrame":"Rotarix vaccination on Day 84 to day 91"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* healthy infants/toddlers as established by medical history and clinical examination before entering study\n* age:\n\n  * toddler cohort: \\> or = 2 and \\<3 years old at the time of enrollment\n  * infant cohort: \\> or = 6 and \\<8 weeks at the time of enrollment\n* parental ability and willingness to provide informed consent\n* parental intention to remain in the area with the child during the study period.\n\nExclusion Criteria:\n\n* Presence of fever on the day of enrollment\n* Acute disease at the time of enrollment\n* Concurrent participation in another clinical trial throughout the entire timeframe for this study\n* Presence of malnutrition or any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination that would compromise the participant's health or is likely to result in nonconformance to the protocol\n* For infant cohort, history of premature birth (\\<37 weeks gestation)\n* History of congenital abdominal disorders, intussusception, or abdominal surgery\n* Known or suspected impairment of immunological function based on medical history and physical examination\n* For infant cohort only, prior receipt of rotavirus vaccine\n* A known sensitivity or allergy to any components of the study vaccine\n* History of anaphylactic reaction\n* Major congenital or genetic defect\n* Participant's parents not able, available or willing to accept active weekly follow-up by the study staff\n* Has received any immunoglobulin therapy and/or blood products since birth or planned administration during the study period\n* History of chronic administration (defined as more than 14 days) of immunosuppressant medications, including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study\n* Any medical condition in the parents/infant that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parents' ability to give informed consent\n* HIV infection\n\n  * For toddlers, to be assessed by HIV ELISA\n  * For infants, to be assessed by PCR, if mother is not known to be negative (negative test result between 24 weeks gestation and screening)","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"35 Months","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Michelle Groome","affiliation":"SAMRC Respiratory and Meningeal Pathogen Research Unit","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Respiratory and Meningeal Pathogens Research Unit (RMPRU)","city":"Johannesburg","state":"Gauteng","zip":"2013","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}}]},"referencesModule":{"references":[{"pmid":"32734176","type":"DERIVED","citation":"Koen A, Jose L, Madhi SA, Fix A, Cryz S, Groome MJ. Neutrophil Counts in Healthy South African Infants: Implications for Enrollment and Adverse Event Grading in Clinical Trials in an African Setting. J Pediatr X. 2019 Spring;1:100005. doi: 10.1016/j.ympdx.2019.100005."},{"pmid":"28483414","type":"DERIVED","citation":"Groome MJ, Koen A, Fix A, Page N, Jose L, Madhi SA, McNeal M, Dally L, Cho I, Power M, Flores J, Cryz S. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017 Aug;17(8):843-853. doi: 10.1016/S1473-3099(17)30242-6. Epub 2017 May 5."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Age de-escalation, dose-escalation study enrolling healthy toddlers and infants between 17 March and 29 September 2014 at a single site in South Africa.","groups":[{"id":"FG000","title":"Cohort A Placebo","description":"Healthy toddlers aged 2 to \\<3 months receiving placebo"},{"id":"FG001","title":"Cohort A 10 mcg P2-VP8","description":"Healthy toddlers 2 to \\<3 yrs of age receiving low dose P2-VP8"},{"id":"FG002","title":"Cohort A 30 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 yrs receiving an intermediate dose of P2-VP8"},{"id":"FG003","title":"Cohort A 60 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\< 3 yrs receiving high dose P2-PV8"},{"id":"FG004","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo"},{"id":"FG005","title":"Cohort B 10 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving low dose P2-VP8"},{"id":"FG006","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks of age receiving a medium dose of P2-VP8"},{"id":"FG007","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving high dose of P2-VP8"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"50"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"50"},{"groupId":"FG007","numSubjects":"50"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"46"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"47"},{"groupId":"FG007","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"2"}]},{"type":"Moved away from study area","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort A Placebo","description":"Healthy toddlers aged 2 to \\< 3 years receiving placebo"},{"id":"BG001","title":"Cohort A 10 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\< 3 years receiving low dose P2-VP8"},{"id":"BG002","title":"Cohort A 30 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\< 3 years receiving Medium Dose Ps-VP9"},{"id":"BG003","title":"Cohort A 60 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\< 3 years receiving High Dose P2-VP8"},{"id":"BG004","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placeblo"},{"id":"BG005","title":"Cohort B 10 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Low Dose P2-VP8"},{"id":"BG006","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8"},{"id":"BG007","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8"},{"id":"BG008","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"50"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"50"},{"groupId":"BG007","value":"50"},{"groupId":"BG008","value":"204"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"136.4","lowerLimit":"126","upperLimit":"143"},{"groupId":"BG001","value":"135.6","lowerLimit":"122","upperLimit":"143"},{"groupId":"BG002","value":"139.0","lowerLimit":"126","upperLimit":"152"},{"groupId":"BG003","value":"144.7","lowerLimit":"139","upperLimit":"152"},{"groupId":"BG004","value":"6.6","lowerLimit":"6.1","upperLimit":"7.7"},{"groupId":"BG005","value":"6.6","lowerLimit":"6.3","upperLimit":"7.0"},{"groupId":"BG006","value":"6.6","lowerLimit":"6.1","upperLimit":"7.7"},{"groupId":"BG007","value":"6.7","lowerLimit":"6.1","upperLimit":"8"},{"groupId":"BG008","value":"72.8","lowerLimit":"6.1","upperLimit":"152"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"23"},{"groupId":"BG007","value":"25"},{"groupId":"BG008","value":"99"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"26"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"27"},{"groupId":"BG007","value":"25"},{"groupId":"BG008","value":"105"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"50"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"49"},{"groupId":"BG007","value":"50"},{"groupId":"BG008","value":"202"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"South Africa","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"50"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"50"},{"groupId":"BG007","value":"50"},{"groupId":"BG008","value":"204"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Vaccine Induced Reactions","description":"Maximum severity of all local reactions or systemic reactogenicity after any vaccination","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days following each dose","groups":[{"id":"OG000","title":"Cohort A Placebo","description":"Healthy toddlers aged 2 to \\<3 months receiving placebo"},{"id":"OG001","title":"Cohort A 10 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 months receiving low dose P2-VP8"},{"id":"OG002","title":"Cohort A 30 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 months receiving Medium Dose P2-VP8"},{"id":"OG003","title":"Cohort A 60 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 months receiving placebo High Dose P2-VP8"},{"id":"OG004","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo"},{"id":"OG005","title":"Cohort B 10 mcg P2-VP8","description":"Healthy infants aged 6 to \\< 8 weeks receiving Low Dose P2-VP8"},{"id":"OG006","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8"},{"id":"OG007","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"50"},{"groupId":"OG007","value":"50"}]}],"classes":[{"title":"None","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"6"}]}]},{"title":"Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"35"},{"groupId":"OG007","value":"37"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"}]}]},{"title":"Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}]}]},{"title":"Life Threatening","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events","description":"Number of participants experiencing a Serious Adverse Event within 28 days of a vaccination and at any time during the study","populationDescription":"All subjects that received at least one dose of P2-VP8 vaccine or placebo","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"within 28 days of a study dose and at any time","groups":[{"id":"OG000","title":"Cohort A Placebo","description":"Healthy toddlers aged 2 to \\<3 years receiving Placebo"},{"id":"OG001","title":"Cohort A 10 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 years receiving Low Dose P2-VP8"},{"id":"OG002","title":"Cohort A 30 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 years receiving Medium Dose P2-VP8"},{"id":"OG003","title":"Cohort A 60 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 years receiving High Dose P2-VP8"},{"id":"OG004","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving Placebo"},{"id":"OG005","title":"Cohort B 10 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Low Dose P2-VP8"},{"id":"OG006","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8"},{"id":"OG007","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"50"},{"groupId":"OG007","value":"50"}]}],"classes":[{"title":"SAE within 28 days of vaccine receipt","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"5"}]}]},{"title":"SAE at any time during follow-up","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Non-Serious Adverse Event","description":"all adverse events will be recorded over the duration of the 6 month follow up period.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"6 mo following first vaccination","groups":[{"id":"OG000","title":"Cohort A Placebo","description":"Healthy toddlers aged 2 to \\<3 months receiving placebo"},{"id":"OG001","title":"Cohort A 10 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 months receiving Low Dose Toddlers P2-VP8"},{"id":"OG002","title":"Cohort A 30 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 months receiving Medium Dose P2-VP8"},{"id":"OG003","title":"Cohort A 60 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 months receiving High Dose P2-VP8"},{"id":"OG004","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo"},{"id":"OG005","title":"Cohort B 10 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Low Dose P2-VP8"},{"id":"OG006","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8"},{"id":"OG007","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose Infants P2-VP8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"50"},{"groupId":"OG007","value":"50"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"46"},{"groupId":"OG007","value":"42"}]}]}]},{"type":"PRIMARY","title":"Number/Percentage of Infant Participants With Anti-P2-VP8 IgA to P[8] Seroresponse.","description":"Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third vaccination). Confidence intervals are displayed as percentages.","populationDescription":"Enrolled infants who received 3 vaccinations and with pre and post-vaccination immunologic parameters measured","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline to day 84","groups":[{"id":"OG000","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo"},{"id":"OG001","title":"Cohort B 10 mcg P2-VP8","description":"Healthy infants aged 6 to \\<8 weeks receiving low dose P2-VP8"},{"id":"OG002","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8"},{"id":"OG003","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"32"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide \\>= 89% and \\>= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide \\> 95% to detect \\>= 40 percentage point difference between a P2-VP8 dose group and placebo group.","pValue":"0.0165","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG000","OG002"],"groupDescription":"Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide \\>= 89% and \\>= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide \\> 95% to detect \\>= 40 percentage point difference between a P2-VP8 dose group and placebo group.","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide \\>= 89% and \\>= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide \\> 95% to detect \\>= 40 percentage point difference between a P2-VP8 dose group and placebo group.","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide \\>= 89% and \\>= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide \\> 95% to detect \\>= 40 percentage point difference between a P2-VP8 dose group and placebo group.","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"PRIMARY","title":"Number/Percentage of Infants With Anti-P2-VP8 IgG to P[8] Seroresponses","description":"Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline to day 84","groups":[{"id":"OG000","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo"},{"id":"OG001","title":"Cohort B 10 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Low Dose P2-VP8"},{"id":"OG002","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8 Medium Dose Infants"},{"id":"OG003","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"47"}]}],"classes":[{"title":"Unadjusted Seroresponse","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"46"}]}]},{"title":"Adjusted Seroresponse","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"47"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Pair-wise comparisons between Cohort B Placebo group and the active vaccination groups were peformed","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Pair-wise comparisons between Cohort B Placebo group and the active vaccination groups were performed","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Pair-wise comparisons between Cohort B Placebo group and the active vaccination groups were performed","pValue":"0.0006","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"PRIMARY","title":"Number/Percentage of Infants With Neutralizing Antibody Response to WA Strain (G1[P8])","description":"Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.","populationDescription":"Enrolled infants who received placebo, 10 mcg, 30 mcg or 60 mcg V2-VP8.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline to Day 84","groups":[{"id":"OG000","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo"},{"id":"OG001","title":"Cohort B 10 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Low Dose P2-VP8"},{"id":"OG002","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8"},{"id":"OG003","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"47"}]}],"classes":[{"title":"Unadjusted seroresponse to neutralizing antibodies","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"}]}]},{"title":"Adjusted seroresponse to neutralizing antibodies","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"A pair wise comparison between the Adjusted Seroresponses in the placebo group and the Group B 10 mcg P2-VP8 was performed.","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide \\>= 89% and \\>= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide \\> 95% to detect \\>= 40 percentage point difference between a P2-VP8 dose group and placebo group.","pValue":"0.0004","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG000","OG002"],"groupDescription":"A pair wise comparison between the Adjusted Seroresponses in the placebo group and the Cohort B 30 mcg P2-VP8 vaccine group was performed.","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide \\>= 89% and \\>= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide \\> 95% to detect \\>= 40 percentage point difference between a P2-VP8 dose group and placebo group.","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG000","OG003"],"groupDescription":"A pair-wise comparison between the Adjusted Seroresponses in Cohort B Placebo group and the Cohort B P2-VP8 group was performed.","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide \\>= 89% and \\>= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide \\> 95% to detect \\>= 40 percentage point difference between a P2-VP8 dose group and placebo group.","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Rotavirus Shedding After Administration of Rotarix in Infants Receiving 3 Doses of Vaccine or Placebo.","description":"Percent of infants who shed rotavirus at any timepoint after receiving 3 doses of study vaccine and one dose of Rotarix. Infants received Rotarix vaccination beginning on Day 84. Stool specimens were collected from these infants on the 5th, 7th and 9th day following first administration of Rotarix. This test was performed as a novel functional assessment of the ability to suppress local gut multiplication of the vaccine strain contained in Rotarix.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Rotarix vaccination on Day 84 to day 91","groups":[{"id":"OG000","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo"},{"id":"OG001","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8"},{"id":"OG002","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"46"}]}],"classes":[{"title":"Any Timepoint - Rotavirus shedding","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}]}]},{"title":"No shedding of rotavirus","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"37"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"28 days after any vaccination","eventGroups":[{"id":"EG000","title":"Cohort A Placebo","description":"Healthy toddlers aged 2 to \\<3 years receiving Placebo","deathsNumAffected":0,"deathsNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"otherNumAffected":2,"otherNumAtRisk":5},{"id":"EG001","title":"Cohort A 10 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 years receiving Low Dose P2-VP8","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":7,"otherNumAtRisk":13},{"id":"EG002","title":"Cohort A 30 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 years receiving Medium Dose P2-VP8","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":6,"otherNumAtRisk":12},{"id":"EG003","title":"Cohort A 60 mcg P2-VP8","description":"Healthy toddlers aged 2 to \\<3 years receiving High Dose P2-VP8","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":8,"otherNumAtRisk":12},{"id":"EG004","title":"Cohort B Placebo","description":"Healthy Infants aged 6 to \\<8 weeks receiving placebo","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":4,"seriousNumAtRisk":50,"otherNumAffected":41,"otherNumAtRisk":50},{"id":"EG005","title":"Cohort B 10 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Low Dose P2-VP8","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG006","title":"Cohort B 30 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving Medium Dose P2-VP8","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":7,"seriousNumAtRisk":50,"otherNumAffected":46,"otherNumAtRisk":50},{"id":"EG007","title":"Cohort B 60 mcg P2-VP8","description":"Healthy Infants aged 6 to \\<8 weeks receiving High Dose P2-VP8","deathsNumAffected":2,"deathsNumAtRisk":50,"seriousNumAffected":8,"seriousNumAtRisk":50,"otherNumAffected":42,"otherNumAtRisk":50}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Acute gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Pulmonary Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG007","numEvents":3,"numAffected":2,"numAtRisk":50}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Staphylococcal impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Infected cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"death","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Death unknown cause","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":50}]}],"otherEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":50}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Body tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":50},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG006","numEvents":8,"numAffected":8,"numAtRisk":50},{"groupId":"EG007","numEvents":8,"numAffected":6,"numAtRisk":50}]},{"term":"Candida nappy rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":50}]},{"term":"Conjuntivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":50}]},{"term":"Helminthic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Otitis media acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":31,"numAffected":24,"numAtRisk":50},{"groupId":"EG005","numEvents":6,"numAffected":5,"numAtRisk":12},{"groupId":"EG006","numEvents":31,"numAffected":25,"numAtRisk":50},{"groupId":"EG007","numEvents":40,"numAffected":30,"numAtRisk":50}]},{"term":"Varicella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Viral Rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Soft Tissue Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":12},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":50},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":50},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":50}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":16,"numAffected":15,"numAtRisk":50},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG006","numEvents":15,"numAffected":14,"numAtRisk":50},{"groupId":"EG007","numEvents":8,"numAffected":7,"numAtRisk":50}]},{"term":"Rhinorrhea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Dermatitiis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":50},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":50},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":50}]},{"term":"Dermatitis diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":8,"numAffected":7,"numAtRisk":50},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Rash Papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":5},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":50}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Michelle J. Groome, MD, PhD","organization":"Chris Hani Baragwanath Academic Hospital","email":"groomem@rmpru.co.za","phone":"+27 11 983 4283"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}